New Haven, CONNECTICUT4 Active Studies

Myelofibrosis Clinical Trials in New Haven, CONNECTICUT

Find 4 actively recruiting myelofibrosis clinical trials in New Haven, CONNECTICUT. Connect with local research sites and explore new treatment options.

4
Active Trials
4
Sponsors
1,309
Enrolling

Recruiting Myelofibrosis Studies in New Haven

RecruitingNew Haven, CONNECTICUTNCT03165734

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia ...

399 participants
Swedish Orphan Biovitrum
View Study Details
RecruitingNew Haven, CONNECTICUTNCT04562389

Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be...

350 participants
Karyopharm Therapeutics Inc
View Study Details
RecruitingNew Haven, CONNECTICUTNCT04576156

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are rela...

320 participants
Geron Corporation
View Study Details
RecruitingNew Haven, CONNECTICUTNCT04176198

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or...

240 participants
Sumitomo Pharma America, Inc.
View Study Details

About Myelofibrosis Clinical Trials in New Haven

Myelofibrosis is a serious bone marrow disorder that disrupts normal blood cell production, leading to extensive scarring in the bone marrow. It can cause severe anemia, weakness, and an enlarged spleen. Treatment includes JAK inhibitors, blood transfusions, and stem cell transplant.

There are currently 4 myelofibrosis clinical trials recruiting participants in New Haven, CONNECTICUT. These studies are seeking a combined 1,309 participants. Research is being sponsored by Swedish Orphan Biovitrum, Karyopharm Therapeutics Inc, Geron Corporation and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myelofibrosis Clinical Trials in New Haven — FAQ

Are there myelofibrosis clinical trials in New Haven?

Yes, there are 4 myelofibrosis clinical trials currently recruiting in New Haven, CONNECTICUT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What myelofibrosis treatments are being tested?

The 4 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for myelofibrosis.

Data updated March 2, 2026 from ClinicalTrials.gov